Spots Global Cancer Trial Database for A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy
Official Title: A Study of ApricityRx™ Digital Therapeutic for Management of Immune-Related Adverse Events in Patients on Immuno-Oncology Therapy
Study ID: NCT04571398
Conditions
Interventions
Study Description
Brief Summary: Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Columbia University Irving Medical Center, New York, New York, United States
Contact Details
Name: Brian Henick, MD
Affiliation: Columbia University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
